{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:02:57Z","timestamp":1788825777716,"version":"build-2803163510"},"reference-count":48,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T00:00:00Z","timestamp":1661472000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Deutsche Derma Gesell"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Background and Objectives<\/jats:title><jats:p>To compare the efficacy and safety of biologic treatments for moderate\u2010to\u2010severe pediatric psoriasis approved by the US Food and Drug Administration and European Medicines Agency.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p>MEDLINE, Embase, and Cochrane Central Register of Controlled Trials for relevant randomized controlled trials (RCTs) were searched for the identification of eligible RCTs until May 7, 2021. Fixed\u2010effect frequentist network meta\u2010analysis (NMA) was performed with the surface under the cumulative ranking curve (SUCRA) calculated for ranking. Our primary outcomes included \u2265\u00a090\u00a0% improvement of Psoriasis Area and Severity Index score (PASI\u00a090) at 12\u201316\u00a0weeks and discontinuation owing to adverse events (DAE) through the first 12\u201316\u00a0weeks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Five RCTs involving 798 pediatric psoriasis patients were included. Compared to placebo, all biologic regimens exhibited a significantly higher PASI\u00a090 response but did not differ in the risk for DAE. Based on the SUCRA, secukinumab\u2010low dose (SEC\u2010L) ranked first in the achieved PASI\u00a090 response (84.7\u00a0%), followed by ixekizumab (70.8\u00a0%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Among all biologic treatments, SEC\u2010L showed the best PASI\u00a090 response without increasing the risk for DAE. More long\u2010term studies are warranted.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ddg.14832","type":"journal-article","created":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T02:35:25Z","timestamp":1661567725000},"page":"1201-1209","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Biologics for pediatric moderate\u2010to\u2010severe plaque psoriasis: a systematic review and network meta\u2010analysis"],"prefix":"10.1111","volume":"20","author":[{"given":"I\u2010Hsin","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Dermatology Chang Gung Memorial Hospital  Linkou Taoyuan Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia\u2010Ling","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Chang Gung Memorial Hospital  Linkou Taoyuan Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng\u2010Chen","family":"Tai","sequence":"additional","affiliation":[{"name":"Medical Library Department of Medical Education Chang Gung Memorial Hospital  Linkou Taoyuan Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu\u2010Kang","family":"Tu","sequence":"additional","affiliation":[{"name":"Institute of Epidemiology and Preventive Medicine College of Public Health National Taiwan University  Taipei Taiwan"},{"name":"Department of Dentistry National Taiwan University Hospital  Taipei Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5699-0283","authenticated-orcid":false,"given":"Ching\u2010Chi","family":"Chi","sequence":"additional","affiliation":[{"name":"Department of Dermatology Chang Gung Memorial Hospital  Linkou Taoyuan Taiwan"},{"name":"School of Medicine, College of Medicine Chang Gung University  Taoyuan Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,8,26]]},"reference":[{"key":"e_1_2_6_2_1","unstructured":"World Health Organization. Global Report on Psoriasis. World Health Organization.2016."},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14507"},{"key":"e_1_2_6_4_1","first-page":"187","article-title":"Prevalence of psoriasis in children and adolescents in the United States: A claims\u2010based analysis","volume":"17","author":"Paller AS","year":"2018","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1470.2001.018003188.x"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2017.0499"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/pde.14208"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10280.x"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.4029"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.01.024"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.08.049"},{"key":"e_1_2_6_12_1","volume-title":"Product Information: Cosentyx\u00ae subcutaneous injection, secukinumab subcutaneous injection. Novartis Pharmaceuticals Corporation (per FDA)","year":"2021"},{"key":"e_1_2_6_13_1","unstructured":"U.S. Food and Drug Administration. Etanercept. U.S. Food and Drug Administration website; Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/103795s5582lbl.pdf[Last accessed on April 12 2022]."},{"key":"e_1_2_6_14_1","unstructured":"European Medicines Agency. Enbrel: EPAR \u2013 Summary for the public. European Medicines Agency website. Available from:https:\/\/www.ema.europa.eu\/en\/documents\/overview\/enbrel\u2010epar\u2010summary\u2010public_en.pdf[Last accessed on April 12 2022]."},{"key":"e_1_2_6_15_1","unstructured":"U.S. Food and Drug Administration. Stelara. U.S. Food and Drug Administration website. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/125261s150lbl.pdf[Last accessed on April 12 2022]."},{"key":"e_1_2_6_16_1","unstructured":"European Medicines Agency. Stelara: EPAR \u2010 Product information. European Medicines Agency website. Available from:https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/stelara[Last accessed on April 12 2022]."},{"key":"e_1_2_6_17_1","unstructured":"U.S. Food and Drug Administration. Cosentyx. U.S. Food and Drug Administration website. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/125504_S050_S051lbl.pdf[Last accessed on April 12 2022]."},{"key":"e_1_2_6_18_1","unstructured":"European Medicines Agency. Cosentyx: EPAR \u2010 Medicine overview. European Medicines Agency website. Available from:https:\/\/www.ema.europa.eu\/en\/documents\/overview\/cosentyx\u2010epar\u2010medicine\u2010overview_en.pdf[Last accessed on April 12 2022]."},{"key":"e_1_2_6_19_1","unstructured":"U.S. Food and Drug Administration. Taltz. U.S. Food and Drug Administration website.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/125521s014lbl.pdf[Last accessed on April 12 2022]."},{"key":"e_1_2_6_20_1","unstructured":"European Medicines Agency. P\/0087\/2020: EMA decision of 18 March 2020 on the acceptance of a modification of an agreed paediatric investigation plan for ixekizumab (Taltz) (EMEA\u2010001050\u2010PIP01\u201010\u2010M05). European Medicines Agency website. Available from:https:\/\/www.ema.europa.eu\/en\/documents\/pip\u2010decision\/p\/0087\/2020\u2010ema\u2010decision\u201018\u2010march\u20102020\u2010acceptance\u2010modification\u2010agreed\u2010paediatric\u2010investigation\u2010plan_en.pdf[Last accessed on April 12 2022]."},{"key":"e_1_2_6_21_1","unstructured":"European Medicines Agency. Humira: EPAR \u2013 Procedural steps taken and scientific information after authorisation. European Medicines Agency website. Available from:https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/humira\u2010epar\u2010product\u2010information_en.pdf[Last accessed on April 12 2022]."},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.7326\/M14-2385"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928"},{"key":"e_1_2_6_24_1","unstructured":"Novartis cosentyx receives FDA approval for treatment of children and adolescents with moderate to severe plaque psoriasis. Novartis. (2021 June 1). Available from:https:\/\/www.novartis.com\/news\/media\u2010releases\/novartis\u2010cosentyx\u2010receives\u2010fda\u2010approval\u2010treatment\u2010children\u2010and\u2010adolescents\u2010moderate\u2010severe\u2010plaque\u2010psoriasis[Last accessed on December 14 2021]."},{"key":"e_1_2_6_25_1","unstructured":"TALTZ (ixekizumab) injection for subcutaneous use Initial U.S. Approval: 2016. The U.S. Food and Drug Administration. (2020 March). Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/125521s020lbl.pdf[Last accessed on April 4 2022]."},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12123629"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1278"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-015-0060-8"},{"key":"e_1_2_6_29_1","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021)","author":"Page MJ","year":"2021"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1044"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1177\/1536867X1501500403"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17002"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19147"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12817"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.05.017"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.11.012"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.05.013"},{"key":"e_1_2_6_38_1","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta\u2010analysis","volume":"1","author":"Sbidian E","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12404"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.07.002"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19018"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.05.056"},{"key":"e_1_2_6_43_1","unstructured":"A study of subcutaneous risankizumab injection for pediatric participants with moderate to severe plaque psoriasis to assess change in disease symptoms. (2020 June 17) Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04435600?recrs=abd&cond=Psoriasis&age=0&draw=2&rank=4[Last accessed on January 18 2022]."},{"key":"e_1_2_6_44_1","unstructured":"A study of tildrakizumab in pediatric subjects with chronic plaque psoriasis. (2019 June 25). Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03997786[Last accessed on February 5 2022]."},{"key":"e_1_2_6_45_1","first-page":"323","article-title":"Efficacy and safety of etanercept in children and adolescents aged \u2265 8 years with severe plaque psoriasis","volume":"20","author":"Landells I","year":"2010","journal-title":"Eur J Dermatol"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.02.060"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa066886"},{"key":"e_1_2_6_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31189-3"},{"key":"e_1_2_6_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18029"}],"container-title":["JDDG: Journal der Deutschen Dermatologischen Gesellschaft"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ddg.14832","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ddg.14832","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ddg.14832","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T11:56:37Z","timestamp":1709812597000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ddg.14832"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,26]]},"references-count":48,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["10.1111\/ddg.14832"],"URL":"https:\/\/doi.org\/10.1111\/ddg.14832","archive":["Portico"],"relation":{},"ISSN":["1610-0379","1610-0387"],"issn-type":[{"value":"1610-0379","type":"print"},{"value":"1610-0387","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,26]]},"assertion":[{"value":"2022-03-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}